Physician profile
Gerald T Rosenberg
NPI 1649249624
$16,624.41
in general payments reported to CMS, 2019-2025
42 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,821 · 2020: $2,515 · 2021: $2,697 · 2022: $1,795 · 2023: $3,071 · 2024: $1,845 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,452 · Consulting Fee: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,452.08 |
| Consulting Fee | $345.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,685.24 | 2019-2025 | Krystexxa, Enbrel, Tavneos |
| Abbvie INC. | $2,048.63 | 2019-2025 | Rinvoq, Skyrizi, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,483.61 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,476.22 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $1,329.51 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $1,022.09 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $895.36 | 2019-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $873.32 | 2019-2024 | Orencia |
| Lilly USA, LLC | $724.53 | 2019-2024 | Taltz |
| Pfizer INC. | $697.21 | 2019-2024 | |
| Pacira Therapeutics, INC. | $542.94 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $460.24 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $354.26 | 2022-2025 | Lupkynis |
| Genzyme Corporation | $332.47 | 2019-2022 | |
| Genentech USA, INC. | $301.86 | 2019-2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $254.38 | 2019-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $187.86 | 2023-2024 | Purified Cortrophin Gel |
| Nevro Corp. | $129.43 | 2019-2024 | Senza |
| Ferring Pharmaceuticals INC. | $118.08 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.18 | 2019-2025 | |
| Fidia Pharma USA INC. | $68.90 | 2020-2021 | |
| Octapharma USA, INC. | $55.00 | 2022-2024 | Octagam Immune Globulin (Human) |
| Bioventus LLC | $45.36 | 2019-2020 | |
| Sobi, INC | $43.34 | 2019-2023 | |
| Medtronic, INC. | $37.41 | 2025 | Stealthstation S8 Platform |
| Cumberland Pharmaceuticals, INC. | $36.57 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $34.98 | 2023-2024 | Idacio |
| Tersera Therapeutics LLC | $33.58 | 2023 | Quzyttir |
| Teva Pharmaceuticals USA, INC. | $33.38 | 2019-2023 | Truxima |
| Ultragenyx Pharmaceutical INC. | $30.06 | 2022 | |
| Hikma Pharmaceuticals USA | $24.45 | 2019-2020 | |
| Almatica Pharma LLC | $22.99 | 2025 | Teriparatide |
| Grifols USA, LLC | $19.37 | 2025 | Gamunex-C |
| Depuy Synthes Sales INC. | $16.96 | 2019 | |
| Abbott Laboratories | $16.85 | 2019 | |
| Antares Pharma, INC. | $15.82 | 2019 | |
| Redhill Biopharma INC. | $15.34 | 2020 | |
| Mylan Institutional INC. | $14.19 | 2023 | |
| Globus Medical, INC. | $14.17 | 2025 | Senza |
| Organon LLC | $14.04 | 2025 | Hadlima |
| Kiniksa Pharmaceuticals, LTD. | $13.04 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.